Related Experiment Video
Updated: Apr 20, 2026
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
Future directions for new medical entities in osteoporosis
1Service of Bone Diseases, Department of Internal Medicine Specialties, Geneva University Hospital and Faculty of Medicine, Switzerland.
Abstract:
Odanacatib, a selective cathepsin K inhibitor, decreases bone resorption, whereas osteoclast number increases and bone formation is maintained, perhaps even increased on some cortical surfaces. In a phase 2 clinical trial, post-menopausal women receiving odanacatib presented a sustained reduction of bone resorption markers, whereas procollagen type 1 N-terminal propeptide returned to normal. In turn areal bone mineral density increased continuously at both spine and hip for up to 5 years. Blosozumab and romosozumab are sclerostin neutralizing antibodies that exert potent anabolic effects on both trabecular and cortical compartments. A phase 2 clinical trial has reported areal bone mineral density gains at spine and hip that were greater with romosozumab compared with placebo, but also with teriparatide. It also showed that antagonizing sclerostin results in a transient stimulation of bone formation but progressive inhibition of bone resorption. Other new medical entities that are promising for the treatment of osteoporosis include abaloparatide, a parathyroid hormone-related analogue with improved bone formation-resorption ratio.
Insights
New osteoporosis treatments like odanacatib and sclerostin inhibitors show promise. These drugs target bone resorption and formation, leading to increased bone mineral density in clinical trials for post-menopausal women.
Area of Science:
- Bone biology and osteoporosis therapeutics.
- Pharmacological interventions for skeletal health.
Background:
- Osteoporosis is characterized by decreased bone mass and increased fracture risk.
- Current treatments primarily focus on inhibiting bone resorption.
Purpose of the Study:
- To review novel therapeutic agents for osteoporosis, including cathepsin K inhibitors and sclerostin antibodies.
- To evaluate their effects on bone resorption, formation, and bone mineral density.
Main Methods:
- Review of clinical trial data for odanacatib, blosozumab, romosozumab, and abaloparatide.
- Analysis of biochemical markers of bone turnover and bone mineral density measurements.
Main Results:
- Odanacatib sustained reduction in bone resorption markers and increased bone mineral density.
- Romosozumab demonstrated significant bone mineral density gains, stimulating bone formation and inhibiting resorption.
- Abaloparatide shows a favorable bone formation-resorption ratio.
Conclusions:
- Selective cathepsin K inhibition and sclerostin antagonism represent promising strategies for osteoporosis treatment.
- These novel agents offer potential for improving bone density and reducing fracture risk.
More Related Videos
07:12Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model
Published on: September 28, 2017
07:00Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
Published on: September 26, 2016
Related Concept Videos
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:31Osteoclasts in Bone Remodeling
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:31Bone Remodeling and Repair
01:40Bone Remodeling